Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Multiple Sclerosis Health Center

Font Size

FDA Lets MS Drug Tysabri Return

Strict Rules Focus on Rare, Potentially Deadly Brain Infection
WebMD Health News
Reviewed by Louise Chang, MD

June 5, 2006 -- The FDA is letting the multiple sclerosis (MS)multiple sclerosis (MS) drug Tysabri back on the market under a restricted distribution program.

The FDA first approved Tysabri in November 2004. Tysabri’s maker, Biogen-Idec, took Tysabri off the market in February 2005 after three people out of about 3,000 patients taking Tysabri in clinical trials developed a rare, serious brain infection called progressive multifocal leukoencephalopathy (PML). Two of those patients died.

The FDA is rolling out a risk-minimization plan along with Tysabri's return to the market. The plan is designed to inform patients, doctors, pharmacists, and infusion centers about Tysabri’s risks and to quickly flag PML cases in patients taking Tysabri.

However, FDA officials aren’t ruling out the possibility of more cases of PML in patients taking the drug.

Rare Return to Market

“This is one of the very rare cases in which a drug withdrawn from the market for safety reasons has been returned back to the market after appropriate steps have been taken,” the FDA’s Steven Galson, MD, MPH, told reporters in a conference call.

Galson directs the FDA’s Center for Drug Evaluation and Research. He says the FDA has worked “closely” with Biogen-Idec on the new plan.

In Tysabri’s clinical trials, about one in 1,000 participants developed PML after taking Tysabri for up to two years. It’s not clear if that rate will hold in the general public or for longer use, the FDA’s Russell Katz, MD, told reporters in the teleconference. Katz works in the neurology products division of the FDA’s Center for Drug Evaluation and Research.

PML is still a risk with Tysabri, note both Galson and Katz.

"Without prohibiting use of the drug, you can never be sure that this won’t happen again. But we think that the steps that we’ve taken are prudent to reduce that risk,” Galson says.

More Cases Possible

“There’s much we don’t know about this,” Katz says. “We expect, yes, that there will be other cases and there probably will be additional deaths. This is balanced against the significant benefit that we believe the drug confers,” Katz says.

1 | 2 | 3

Today on WebMD

nerve damage
Learn how this disease affects the nervous system.
woman applying lotion
Ideas on how to boost your mood and self-esteem.
woman pondering
Get personalized treatment options.
man with hand over eye
Be on the lookout for these symptoms.
brain scan
worried woman
neural fiber
white blood cells
sunlight in hands
marijuana plant
muscle spasm